The question of whether “felon” will be another moniker attached to Martin Shkreli, a former pharmaceutical executive standing trial for securities and wire fraud who has been given the tongue-in-cheek nickname “Pharma Bro,” was placed July 28 in the hands of a federal jury in Brooklyn.

While better known as the man responsible for increasing the price of an antiparasitic drug by 5,000 percent, Shkreli is accused of running a form of Ponzi scheme in which he defrauded investors into two hedge funds he created and paid them back by misappropriating $11 million in assets from Retrophin, which he also founded.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]